Claret Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $233K | Buy |
+1,854
| New | +$233K | 0.03% | 320 |
|
|
2025
Q1 | – | Sell |
-1,494
| Closed | -$204K | – | 334 |
|
|
2024
Q4 | $204K | Buy |
+1,494
| New | +$204K | 0.03% | 287 |
|
|
2024
Q2 | – | Sell |
-1,451
| Closed | -$200K | – | 281 |
|
|
2024
Q1 | $200K | Sell |
1,451
-114
| -7% | -$15.7K | 0.03% | 200 |
|
|
2023
Q4 | $206K | Buy |
+1,565
| New | +$206K | 0.04% | 169 |
|